Sutro Biopharma, Inc. (STRO) Investor Relations Documents

Sutro Biopharma, Inc. (STRO) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-08-11. Read in-app with summaries. First-party data.

Corporate Presentation: Sutro Biopharma (STRO) is a clinical-stage oncology company developing next-generation ADCs, with a cash runway extending into at least the second quarter of 2028.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-12Press releaseSutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
2026-08-11PresentationCorporate Presentation
2026-05-14Press releaseSutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-14PresentationCorporate Presentation View Presentation
2026-05-14Press releasePDF
2026-04-19Press releaseSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC P
2026-03-23Press releaseSutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
2026-03-23Press releasePDF
2026-02-25Press releaseSutro Biopharma to Participate in Upcoming Investor Conferences
2026-02-23Press releaseSutro Biopharma Announces Participation at the 16th World ADC London Summit
2026-02-10Press releaseSutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
2026-01-07Press releaseSutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-06Press releasePDF
2025-08-07Press releasePDF
2025-05-08Press releasePDF
2025-03-13Press releasePDF
2025-03-13Press releaseSutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
2025-03-13Press releaseEarnings Release FY 2024 PDF
2024-11-13Press releasePDF
2024-11-13Press releaseSutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
2024-11-13Press releaseEarnings Release Q3 2024 PDF
2024-10-10Press releaseSutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
2024-09-11Press releaseSutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10
2024-08-13Press releasePDF
2024-08-13Press releaseEarnings Release Q2 2024 PDF
2024-05-13Press releasePDF
2024-03-25Press releasePDF
2024-03-25Press releaseSutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-11-13Press releasePDF
2023-11-13Press releaseSutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-08-10Press releasePDF
2023-08-10Press releaseSutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-05-15Press releasePDF
2023-05-15Press releaseSutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
2023-03-30Press releasePDF
2023-03-30Press releaseSutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
2022-11-08Press releasePDF
2022-11-08Press releaseSutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
2022-08-08Press releasePDF
2022-08-08Press releaseEarnings Release HTML

STRO overview · STRO earnings · STRO financials · STRO KPIs · STRO ownership · STRO peers · STRO filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.